Concise review: Using stem cells to prevent the progression of myopia - A concept

Research output: Contribution to journalArticle

Abstract

The prevalence of myopia has increased in modern society due to the educational load of children. This condition is growing rapidly, especially in Asian countries where it has already reached a pandemic level. Typically, the younger the child's age at the onset of myopia, the more rapidly the condition will progress and the greater the likelihood that it will develop the known sight-threatening complications of high myopia. This rise in incidence of severe myopia has contributed to an increased frequency of eye diseases in adulthood, which often complicate therapeutic procedures. Currently, no treatment is available to prevent myopia progression. Stem cell therapy can potentially address two components of myopia. Regardless of the exact etiology, myopia is always associated with scleral weakness. In this context, a strategy aimed at scleral reinforcement by transplanting connective tissue-supportive mesenchymal stem cells is an attractive approach that could yield effective and universal therapy. Sunlight exposure appears to have a protective effect against myopia. It is postulated that this effect is mediated via local ocular production of dopamine. With a variety of dopamine-producing cells already available for the treatment of Parkinson's disease, stem cells engineered for dopamine production could be used for the treatment of myopia. In this review, we further explore these concepts and present evidence from the literature to support the use of stem cell therapy for the treatment of myopia. Stem Cells 2015;33:2104-2113

Original languageEnglish (US)
Pages (from-to)2104-2113
Number of pages10
JournalStem Cells
Volume33
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Myopia
Stem Cells
Dopamine
Cell- and Tissue-Based Therapy
Therapeutics
Eye Diseases
Sunlight
Pandemics
Mesenchymal Stromal Cells
Age of Onset
Connective Tissue
Parkinson Disease
Incidence

Keywords

  • Dopamine
  • Eye
  • Mesenchymal
  • Myopia
  • Nearsightedness
  • Sclera
  • Stem cells

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Concise review : Using stem cells to prevent the progression of myopia - A concept. / Janowski, Miroslaw; Bulte, Jeff W; Handa, James; Rini, David A; Walczak, Piotr.

In: Stem Cells, Vol. 33, No. 7, 01.07.2015, p. 2104-2113.

Research output: Contribution to journalArticle

@article{ffd297eb7eb14d8a8dfbd96e4cec8512,
title = "Concise review: Using stem cells to prevent the progression of myopia - A concept",
abstract = "The prevalence of myopia has increased in modern society due to the educational load of children. This condition is growing rapidly, especially in Asian countries where it has already reached a pandemic level. Typically, the younger the child's age at the onset of myopia, the more rapidly the condition will progress and the greater the likelihood that it will develop the known sight-threatening complications of high myopia. This rise in incidence of severe myopia has contributed to an increased frequency of eye diseases in adulthood, which often complicate therapeutic procedures. Currently, no treatment is available to prevent myopia progression. Stem cell therapy can potentially address two components of myopia. Regardless of the exact etiology, myopia is always associated with scleral weakness. In this context, a strategy aimed at scleral reinforcement by transplanting connective tissue-supportive mesenchymal stem cells is an attractive approach that could yield effective and universal therapy. Sunlight exposure appears to have a protective effect against myopia. It is postulated that this effect is mediated via local ocular production of dopamine. With a variety of dopamine-producing cells already available for the treatment of Parkinson's disease, stem cells engineered for dopamine production could be used for the treatment of myopia. In this review, we further explore these concepts and present evidence from the literature to support the use of stem cell therapy for the treatment of myopia. Stem Cells 2015;33:2104-2113",
keywords = "Dopamine, Eye, Mesenchymal, Myopia, Nearsightedness, Sclera, Stem cells",
author = "Miroslaw Janowski and Bulte, {Jeff W} and James Handa and Rini, {David A} and Piotr Walczak",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/stem.1984",
language = "English (US)",
volume = "33",
pages = "2104--2113",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Concise review

T2 - Using stem cells to prevent the progression of myopia - A concept

AU - Janowski, Miroslaw

AU - Bulte, Jeff W

AU - Handa, James

AU - Rini, David A

AU - Walczak, Piotr

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The prevalence of myopia has increased in modern society due to the educational load of children. This condition is growing rapidly, especially in Asian countries where it has already reached a pandemic level. Typically, the younger the child's age at the onset of myopia, the more rapidly the condition will progress and the greater the likelihood that it will develop the known sight-threatening complications of high myopia. This rise in incidence of severe myopia has contributed to an increased frequency of eye diseases in adulthood, which often complicate therapeutic procedures. Currently, no treatment is available to prevent myopia progression. Stem cell therapy can potentially address two components of myopia. Regardless of the exact etiology, myopia is always associated with scleral weakness. In this context, a strategy aimed at scleral reinforcement by transplanting connective tissue-supportive mesenchymal stem cells is an attractive approach that could yield effective and universal therapy. Sunlight exposure appears to have a protective effect against myopia. It is postulated that this effect is mediated via local ocular production of dopamine. With a variety of dopamine-producing cells already available for the treatment of Parkinson's disease, stem cells engineered for dopamine production could be used for the treatment of myopia. In this review, we further explore these concepts and present evidence from the literature to support the use of stem cell therapy for the treatment of myopia. Stem Cells 2015;33:2104-2113

AB - The prevalence of myopia has increased in modern society due to the educational load of children. This condition is growing rapidly, especially in Asian countries where it has already reached a pandemic level. Typically, the younger the child's age at the onset of myopia, the more rapidly the condition will progress and the greater the likelihood that it will develop the known sight-threatening complications of high myopia. This rise in incidence of severe myopia has contributed to an increased frequency of eye diseases in adulthood, which often complicate therapeutic procedures. Currently, no treatment is available to prevent myopia progression. Stem cell therapy can potentially address two components of myopia. Regardless of the exact etiology, myopia is always associated with scleral weakness. In this context, a strategy aimed at scleral reinforcement by transplanting connective tissue-supportive mesenchymal stem cells is an attractive approach that could yield effective and universal therapy. Sunlight exposure appears to have a protective effect against myopia. It is postulated that this effect is mediated via local ocular production of dopamine. With a variety of dopamine-producing cells already available for the treatment of Parkinson's disease, stem cells engineered for dopamine production could be used for the treatment of myopia. In this review, we further explore these concepts and present evidence from the literature to support the use of stem cell therapy for the treatment of myopia. Stem Cells 2015;33:2104-2113

KW - Dopamine

KW - Eye

KW - Mesenchymal

KW - Myopia

KW - Nearsightedness

KW - Sclera

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84931564777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931564777&partnerID=8YFLogxK

U2 - 10.1002/stem.1984

DO - 10.1002/stem.1984

M3 - Article

C2 - 25752937

AN - SCOPUS:84931564777

VL - 33

SP - 2104

EP - 2113

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 7

ER -